Merck Discontinues Two More Phase III Keytruda Studies

 
• By Joseph Haas

Merck & Co. is stopping a combo study of Keytruda and radiotherapy in lung cancer and a monotherapy melanoma study, but 1,600 ongoing trials remain.

Pembrolizumab
Merck said it is giving up on two Phase III label-expansion studies for Keytruda • Source: Shutterstock

More from Immuno-oncology

More from Anticancer